

AMENDMENTS TO THE CLAIMS:

The listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF THE CLAIMS

1. (Canceled).
2. (Canceled).
3. (Canceled).
4. (Canceled).
5. (Canceled).
6. (Canceled).
7. (Previously Presented) A method for inhibiting abnormal bradykinin-induced myometrial contraction, comprising administering to the patient in need of treatment, a therapeutically effective amount of adrenomedullin, wherein the adrenomedullin is:
 - (a.) a peptide comprising an amino acid sequence from Ser in position 13 to Tyr in position 52 of SEQ ID NO: 2.
8. (Previously Presented) A method for inhibiting abnormal bradykinin-induced myometrial contraction, comprising administering to the patient in need of treatment, a therapeutically effective amount of adrenomedullin, wherein the adrenomedullin is:
 - (b.) a peptide comprising an amino acid sequence from Tyr in position 1 to Tyr in position 52 of SEQ ID NO: 2.

9. (Previously Presented) A method for inhibiting abnormal bradykinin-induced myometrial contraction, comprising administering to the patient in need of treatment, a therapeutically effective amount of adrenomedullin, wherein the adrenomedullin is:

(c.) a peptide comprising an amino acid sequence from Ala in position -73 to Tyr in position 52 of SEQ ID NO: 2.

10. (Previously Presented) A method for inhibiting abnormal bradykinin-induced myometrial contraction, comprising administering to the patient in need of treatment, a therapeutically effective amount of adrenomedullin, wherein the adrenomedullin is:

(d.) a peptide comprising an amino acid sequence from Met in position -94 to Leu in position 91 of SEQ ID NO: 2.

11. (Previously Presented) A method according to claim 10, wherein the C-terminus of the adrenomedullin is amidated.

12. (Previously Presented) A method according to claim 10, wherein Gly is added to the C-terminus of the adrenomedullin.

13. (Previously Presented) A method according to claim 10, wherein in the adrenomedullin, Cys in position 16 and Cys in position 21 of SEQ ID NO: 2 are crosslinked.

14. (Previously Presented) A method according to claim 13, wherein the crosslink is a disulfide bond.

15. (Previously Presented) A method according to claim 13, wherein the crosslink is a $-CH_2-CH_2-$ bond.

16. (Canceled).

17. (Canceled).

18. (Canceled).

19. (Canceled).
20. (Canceled).
21. (Canceled).
22. (Canceled).
23. (New) A method according to claim 7, wherein the C-terminus of the adrenomedullin is amidated.
24. (New) A method according to claim 7, wherein Gly is added to the C-terminus of the adrenomedullin.
25. (New) A method according to claim 7, wherein in the adrenomedullin, Cys in position 16 and Cys in position 21 of SEQ ID NO: 2 are crosslinked.
26. (New) A method according to claim 25, wherein the crosslink is a disulfide bond.
27. (New) A method according to claim 25, wherein the crosslink is a $-\text{CH}_2-\text{CH}_2-$ bond.
28. (New) A method according to claim 8, wherein the C-terminus of the adrenomedullin is amidated.
29. (New) A method according to claim 8, wherein Gly is added to the C-terminus of the adrenomedullin.
30. (New) A method according to claim 8, wherein in the adrenomedullin, Cys in position 16 and Cys in position 21 of SEQ ID NO: 2 are crosslinked.

31. (New) A method according to claim 30, wherein the crosslink is a disulfide bond.

32. (New) A method according to claim 30, wherein the crosslink is a $\text{-CH}_2\text{-CH}_2\text{-}$ bond.

33. (New) A method according to claim 9, wherein the C-terminus of the adrenomedullin is amidated.

34. (New) A method according to claim 9, wherein Gly is added to the C-terminus of the adrenomedullin.

35. (New) A method according to claim 9, wherein in the adrenomedullin, Cys in position 16 and Cys in position 21 of SEQ ID NO: 2 are crosslinked.

36. (New) A method according to claim 35, wherein the crosslink is a disulfide bond.

37. (New) A method according to claim 35, wherein the crosslink is a $\text{-CH}_2\text{-CH}_2\text{-}$ bond.